Tislelizumab with chemotherapy for previously
untreated advanced oesophageal squamous cell
carcinoma

Tislelizumab with chemotherapy is in clinical development to treat patients with advanced
oesophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that begins in the thin,
flat cells lining the food pipe (oesophagus) and may spread to other parts of the body. Symptoms
include difficulty swallowing, persistent indigestion or heartburn, weight loss, pain in the throat,
and chronic cough. In the UK it is more common in older people (≥75 years old) and males. There
is a need for new treatment options, including immunotherapies, as ESCC progresses rapidly and
is associated with a high mortality.